These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

190 related articles for article (PubMed ID: 26947567)

  • 1. Early Formation of Serum Advanced Glycation End-Products in Children with Type 1 Diabetes Mellitus: Relationship with Glycemic Control.
    Jaisson S; Souchon PF; Desmons A; Salmon AS; Delemer B; Gillery P
    J Pediatr; 2016 May; 172():56-62. PubMed ID: 26947567
    [TBL] [Abstract][Full Text] [Related]  

  • 2. HbA1c and serum levels of advanced glycation and oxidation protein products in poorly and well controlled children and adolescents with type 1 diabetes mellitus.
    Kostolanská J; Jakus V; Barák L
    J Pediatr Endocrinol Metab; 2009 May; 22(5):433-42. PubMed ID: 19618662
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Serum levels of advanced glycation end products in poorly metabolically controlled children with diabetes mellitus: relation to HbA1c.
    Jakus V; Bauerová K; Michalková D; Cársky J
    Diabetes Nutr Metab; 2001 Aug; 14(4):207-11. PubMed ID: 11716290
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Advanced glycation end products in children and adolescents with diabetes: relation to glycemic control and early microvascular complications.
    Chiarelli F; de Martino M; Mezzetti A; Catino M; Morgese G; Cuccurullo F; Verrotti A
    J Pediatr; 1999 Apr; 134(4):486-91. PubMed ID: 10190925
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Improvement in quality of diabetes control and concentrations of AGE-products in patients with type 1 and insulin-treated type 2 diabetes mellitus studied over a period of 10 years (JEVIN).
    Schiel R; Franke S; Appel T; Voigt U; Ross IS; Kientsch-Engel R; Stein G; Müller UA
    J Diabetes Complications; 2003; 17(2):90-7. PubMed ID: 12614975
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Plasma advanced glycation end products and the subsequent risk of microvascular complications in type 1 diabetes in the DCCT/EDIC.
    Monnier VM; Sell DR; Gao X; Genuth SM; Lachin JM; Bebu I;
    BMJ Open Diabetes Res Care; 2022 Jan; 10(1):. PubMed ID: 35058313
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Small- and large-fiber neuropathy after 40 years of type 1 diabetes: associations with glycemic control and advanced protein glycation: the Oslo Study.
    Sveen KA; Karimé B; Jørum E; Mellgren SI; Fagerland MW; Monnier VM; Dahl-Jørgensen K; Hanssen KF
    Diabetes Care; 2013 Nov; 36(11):3712-7. PubMed ID: 24026557
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Serum levels of non-carboxymethyllysine advanced glycation endproducts are correlated to severity of microvascular complications in patients with Type 1 diabetes.
    Miura J; Yamagishi Si; Uchigata Y; Takeuchi M; Yamamoto H; Makita Z; Iwamoto Y
    J Diabetes Complications; 2003; 17(1):16-21. PubMed ID: 12505751
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Development and Application of Mass Spectroscopy Assays for Nε-(1-Carboxymethyl)-L-Lysine and Pentosidine in Renal Failure and Diabetes.
    O'Grady KL; Khosla S; Farr JN; Bondar OP; Atkinson EJ; Achenbach SJ; Eckhardt BA; Thicke BS; Tweed AJ; Volkman TL; Drake MT; Hines JM; Singh RJ
    J Appl Lab Med; 2020 May; 5(3):558-568. PubMed ID: 32445362
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Comparative study of serum/plasma glycation and lipid peroxidation of young patients with type 1 diabetes mellitus in relation to glycemic compensation and the occurrence of diabetic complications.
    Kostolanska J; Jakus V; Barak L; Stanikova A; Waczulikova I
    Bratisl Lek Listy; 2010; 111(11):578-85. PubMed ID: 21384742
    [TBL] [Abstract][Full Text] [Related]  

  • 11. The impact of salsalate treatment on serum levels of advanced glycation end products in type 2 diabetes.
    Barzilay JI; Jablonski KA; Fonseca V; Shoelson SE; Goldfine AB; Strauch C; Monnier VM;
    Diabetes Care; 2014 Apr; 37(4):1083-91. PubMed ID: 24255104
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Impact of metabolic control and serum lipids on the concentration of advanced glycation end products in the serum of children and adolescents with type 1 diabetes, as determined by fluorescence spectroscopy and nepsilon-(carboxymethyl)lysine ELISA.
    Galler A; Müller G; Schinzel R; Kratzsch J; Kiess W; Münch G
    Diabetes Care; 2003 Sep; 26(9):2609-15. PubMed ID: 12941727
    [TBL] [Abstract][Full Text] [Related]  

  • 13. The advanced glycation end product Nepsilon-(carboxymethyl)lysine is increased in serum from children and adolescents with type 1 diabetes.
    Berg TJ; Clausen JT; Torjesen PA; Dahl-Jørgensen K; Bangstad HJ; Hanssen KF
    Diabetes Care; 1998 Nov; 21(11):1997-2002. PubMed ID: 9802757
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Distinct associations of HbA1c and the urinary excretion of pentosidine, an advanced glycosylation end-product, with markers of endothelial function in insulin-dependent diabetes mellitus.
    Smulders RA; Stehouwer CD; Schalkwijk CG; Donker AJ; van Hinsbergh VW; TeKoppele JM
    Thromb Haemost; 1998 Jul; 80(1):52-7. PubMed ID: 9684785
    [TBL] [Abstract][Full Text] [Related]  

  • 15. The effects of n-3 long-chain polyunsaturated fatty acid supplementation on AGEs and sRAGE in type 2 diabetes mellitus.
    Kurt A; Andican G; Siva ZO; Andican A; Burcak G
    J Physiol Biochem; 2016 Dec; 72(4):679-687. PubMed ID: 27448155
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Evaluation of autofluorescent property of hemoglobin-advanced glycation end product as a long-term glycemic index of diabetes.
    Gopalkrishnapillai B; Nadanathangam V; Karmakar N; Anand S; Misra A
    Diabetes; 2003 Apr; 52(4):1041-6. PubMed ID: 12663478
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Comparison of advanced glycation endproducts on haemoglobin (Hb-AGE) and haemoglobin A1c for the assessment of diabetic control.
    Turk Z; Mesić R; Benko B
    Clin Chim Acta; 1998 Oct; 277(2):159-70. PubMed ID: 9853699
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Time course of specific AGEs during optimised glycaemic control in type 2 diabetes.
    Mentink CJ; Kilhovd BK; Rondas-Colbers GJ; Torjesen PA; Wolffenbuttel BH
    Neth J Med; 2006 Jan; 64(1):10-6. PubMed ID: 16421436
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Advanced glycation end products are associated with arterial stiffness in type 1 diabetes.
    Llauradó G; Ceperuelo-Mallafré V; Vilardell C; Simó R; Gil P; Cano A; Vendrell J; González-Clemente JM
    J Endocrinol; 2014 Jun; 221(3):405-13. PubMed ID: 24681829
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Pentosidine and N-carboxymethyl-lysine: biomarkers for type 2 diabetic retinopathy.
    Ghanem AA; Elewa A; Arafa LF
    Eur J Ophthalmol; 2011; 21(1):48-54. PubMed ID: 20544678
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.